ID | 62412 |
FullText URL | |
Author |
Matsumoto, Kazuyuki
Department of Gastroenterology and Hepatology, Okayama University Hospital
ORCID
Kaken ID
publons
Kato, Hironari
Department of Gastroenterology and Hepatology, Okayama University Hospital
ORCID
Kaken ID
researchmap
Kitano, Masayuki
Second Department of Internal Medicine, Wakayama Medical University
Hara, Kazuo
Gastroenterology, Aichi Cancer Center
Kuwatani, Masaki
Gastroenterology and Hepatology, Hokkaido University Hospital
Ashida, Reiko
Second Department of Internal Medicine, Wakayama Medical University
Takenaka, Mamoru
Department of Gastroenterology and Hepatology, Kindai University
Yamazaki, Tatsuhiro
Department of Gastroenterology and Hepatology, Okayama University Hospital
Sakurai, Jun
Center for Innovative Clinical Medicine, Okayama University Hospital
Yoshida, Michihiro
Center for Innovative Clinical Medicine, Okayama University Hospital
Okada, Hiroyuki
Department of Gastroenterology and Hepatology, Okayama University Hospital
Kaken ID
publons
researchmap
|
Abstract | Introduction The management of small pancreatic neuroendocrine neoplasms (PNENs) remains controversial. The standard treatment for PNENs is surgical resection; however, invasiveness of surgical procedure remains higher and the incidence of postoperative adverse events is still high. Recently, the efficacy and safety of endoscopic ultrasonography (EUS)-guided ethanol injection for small PNENs has been preliminarily demonstrated. Thus, a multicentre prospective study is being conducted to evaluate the efficacy and safety of EUS-guided ethanol injection therapy for small PNENs. Methods and analysis The major eligibility criteria are the presence of pathologically diagnosed grade (G) 1 tumour, a tumour size of <= 15 mm and non-functional PNEN or insulinoma. For treatment, we will use a 25-gauge needle and pure ethanol. Contrast-enhanced CT (CE-CT) will be performed on postoperative day 3-5, and if enhanced areas of the tumour are still apparent, an additional session is scheduled during the same hospitalisation period. We set the total amount of ethanol per session to 2 mL. To evaluate the efficacy and safety, CE-CT will be performed at 1 and 6 months after treatment. The primary endpoint is the percentage of subjects who achieved all of the following evaluated points. Efficacy will be evaluated based on the achievement of complete ablation (defined as no enhanced area within the tumour on CE-CT) at 1 and 6 months. Safety will be evaluated based on the avoidance of severe adverse events within 1 month after treatment, continuing severe pancreatic fistula at 1 month after treatment and the incidence and/or exacerbation of diabetes mellitus at 6 months after treatment. Ethics and dissemination This protocol has been approved by Okayama University Certified Review Board (approval number. CRB19-007). The results will be submitted to peer-reviewed journals and will be presented at international conferences.
|
Keywords | gastroenterology
endoscopy
pancreatic disease
|
Published Date | 2021
|
Publication Title |
BMJ Open
|
Volume | volume11
|
Issue | issue7
|
Publisher | BMJ Publishing Group
|
Start Page | e046505
|
ISSN | 2044-6055
|
Content Type |
Journal Article
|
language |
English
|
OAI-PMH Set |
岡山大学
|
Copyright Holders | © Author(s) (or their employer(s)) 2021.
|
File Version | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
Related Url | isVersionOf https://doi.org/10.1136/bmjopen-2020-046505
|
License | http://creativecommons.org/licenses/by-nc/4.0/
|